Literature DB >> 28537038

The EXXERT Study.

Randall C Thompson1, Gregory S Thomas2,3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28537038     DOI： 10.1007/s12350-017-0903-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  9 in total

1.  Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging.

Authors:  Alan W Ahlberg; Sarkis B Baghdasarian; Haris Athar; Jeffrey P Thompsen; Deborah M Katten; Gavin L Noble; Igor Mamkin; Anuj R Shah; Ivette A Leka; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

2.  A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.

Authors:  Matthew W Parker; Donna Chelle Morales; Hanna B Slim; Alan W Ahlberg; Deborah M Katten; Giselle Cyr; Shishir Mathur; Afrooz Ardestani; Dimitrios Barmpouletos; Geeta Swamy Iyah; Steven M Borer; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2012-11-28       Impact factor: 5.952

3.  Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.

Authors:  Randall C Thompson; Harshal Patil; Elaine C Thompson; Gregory S Thomas; Mohammed Al-Amoodi; Kevin F Kennedy; Kevin A Bybee; A Iain McGhie; James H O'Keefe; Lisa Oakes; Timothy M Bateman
Journal:  J Nucl Cardiol       Date:  2012-12-12       Impact factor: 5.952

4.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

5.  Independent prognostic significance of ischemic ST-segment response limited to recovery from treadmill exercise in asymptomatic subjects.

Authors:  T M Rywik; R C Zink; N S Gittings; A A Khan; J G Wright; F C O'Connor; J L Fleg
Journal:  Circulation       Date:  1998-06-02       Impact factor: 29.690

6.  Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Authors:  M I Ross; E Wu; J T Wilkins; D Gupta; S Shen; D Aulwes; K Montero; T A Holly
Journal:  J Nucl Cardiol       Date:  2013-02-13       Impact factor: 5.952

7.  Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.

Authors:  Sara L Partington; Viswanatha Lanka; Jon Hainer; Ron Blankstein; Hicham Skali; Daniel E Forman; Marcelo F Di Carli; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2012-05-08       Impact factor: 5.952

8.  The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.

Authors:  Gregory S Thomas; Randall C Thompson; Michael I Miyamoto; Tze K Ip; Deborah L Rice; Douglas Milikien; Hsiao D Lieu; Vandana S Mathur
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

9.  The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.

Authors:  Gregory S Thomas; S James Cullom; Therese M Kitt; Kathleen M Feaheny; Karthikeyan Ananthasubramaniam; Robert J Gropler; Diwakar Jain; Randall C Thompson
Journal:  J Nucl Cardiol       Date:  2017-02-21       Impact factor: 5.952
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.